Effects of defined gut microbial ecosystem components on virulence determinants of Clostridioides difficile

• Published in: Scientific reports 2019-01, Vol.9 (1), p.885-885, Article 885
• Main Authors: Carlucci, Christian, Jones, Carys S., Oliphant, Kaitlyn, Yen, Sandi, Daigneault, Michelle, Carriero, Charley, Robinson, Avery, Petrof, Elaine O., Weese, J. Scott, Allen-Vercoe, Emma
• Format: Article
• Language: English
• Subjects: 140/131; 38/22; 38/23; 38/39; 38/77; 38/90; 631/326/2565/2134; 631/326/421; Anti-Bacterial Agents - pharmacology; Bacterial Proteins - genetics; Bacterial Toxins - pharmacology; CD18 antigen; Ciprofloxacin; Ciprofloxacin - pharmacology; Clostridiales - genetics; Clostridiales - metabolism; Clostridioides difficile - genetics; Clostridioides difficile - metabolism; Clostridium Infections - microbiology; Diarrhea; Diarrhea - microbiology; Drug development; Dysbiosis - microbiology; Ecosystems; Enterotoxins - pharmacology; Fecal Microbiota Transplantation - methods; Feces - microbiology; Gastrointestinal Microbiome - genetics; Humanities and Social Sciences; Humans; Intestinal microflora; Metabolites; Microbiota; Microbiota - genetics; multidisciplinary; Patients; Science; Science (multidisciplinary); Secretion; Strains (organisms); Virulence; Virulence - genetics; Virulence Factors - pharmacology
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-018-37547-x

Many cases of Clostridioides difficile infection (CDI) are poorly responsive to standard antibiotic treatment strategies, and often patients suffer from recurrent infections characterized by severe diarrhea. Our group previously reported the successful cure of two patients with recurrent CDI using a standardized stool-derived microbial ecosystem therapeutic (MET-1). Using an in vitro model of the distal gut to support bacterial communities, we characterized the metabolite profiles of two defined microbial ecosystems derived from healthy donor stool (DEC58, and a subset community, MET-1), as well as an ecosystem representative of a dysbiotic state (ciprofloxacin-treated DEC58). The growth and virulence determinants of two C. difficile strains were then assessed in response to components derived from the ecosystems. CD186 (ribotype 027) and CD973 (ribotype 078) growth was decreased upon treatment with DEC58 metabolites compared to ciprofloxacin-treated DEC58 metabolites. Furthermore, CD186 TcdA and TcdB secretion was increased following treatment with ciprofloxacin-treated DEC58 spent medium compared to DEC58 spent medium alone. The net metabolic output of C. difficile was also modulated in response to spent media from defined microbial ecosystems, although several metabolite levels were divergent across the two strains examined. Further investigation of these antagonistic properties will guide the development of microbiota-based therapeutics for CDI.